Oliver A. Cornely
Expertise in
23
conditions

Oliver A. Cornely

Kerpener Str. 62, 
Koeln, NW, DE 
Expertise in
23
conditions
Kerpener Str. 62, 
Koeln, NW, DE 

Overview

Oliver Cornely practices practicing medicine in Koeln, Germany.

Mr. Cornely is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Mucormycosis, Aspergillosis, COVID-19, Agranulocytosis, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 610 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Kerpener Str. 62, Koeln, NW 50937, Germany
Other Locations
Gleueler Str. 269, Koeln, NW 50935, Germany
Joseph Stelzmann Str. 26, Koeln, NW 50931, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (≥75) Already Vaccinated Against SARS-COV-2 (EU-COVAT-1_AGED)
A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (≥75) Already Vaccinated Against SARS-COV-2 (EU-COVAT-1_AGED)
Enrollment Status: Completed
Publish Date: May 20, 2025
Intervention Type: Biological
Study Phase: Phase 2
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Enrollment Status: Completed
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drug: Ibrexafungerp
Study Phase: Phase 3
An Open Label, Multi-Center Study to Determine the Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia With Neutropenia
An Open Label, Multi-Center Study to Determine the Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia With Neutropenia
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Drug
Study Phase: Phase 1
ImPACt on Invasive Fungal Infections by Immune Checkpoint Inhibition
ImPACt on Invasive Fungal Infections by Immune Checkpoint Inhibition
Enrollment Status: Completed
Publish Date: November 01, 2022
Intervention Type: Other
A Phase I/ Randomized Phase II Trial to Analyse Safety and Efficacy of Human SARS-CoV-2-specific T Lymphocyte Transfer in Patients With COVID-19 in Need of Treatment or at Risk of Severe COVID-19
A Phase I/ Randomized Phase II Trial to Analyse Safety and Efficacy of Human SARS-CoV-2-specific T Lymphocyte Transfer in Patients With COVID-19 in Need of Treatment or at Risk of Severe COVID-19
Enrollment Status: Terminated
Publish Date: September 15, 2022
Intervention Type: Drug
Study Drug: Human SARS-CoV 2 Specific T Lymphocytes
Study Phase: Phase 1
View 4 Less Clinical Trials

610 Total Publications

Why intrinsic reduced susceptibility in rare fungal pathogens should be differentiated from intrinsic resistance: an ISHAM conceptual framework and narrative review.
Why intrinsic reduced susceptibility in rare fungal pathogens should be differentiated from intrinsic resistance: an ISHAM conceptual framework and narrative review.
Journal: Antimicrobial agents and chemotherapy
Published: June 10, 2026

Frequently Asked Questions about Oliver A. Cornely

Is Oliver A. Cornely a top-rated expert for Mucormycosis?

MediFind is an objective health platform that identifies experts based on real-world data. Oliver A. Cornely is classified as an Elite expert for Mucormycosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Oliver A. Cornely participate in research or clinical trials?

Yes. Oliver A. Cornely has published 610 articles and abstracts on conditions like Mucormycosis. You can view a list of Oliver A. Cornely's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cornely's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 48 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile